67882-97-7

Basic information

• Product Name: (E)-4-(4-Hydroxystyryl)pyridine
• Synonyms: (E)-4-(4-Hydroxystyryl)pyridine;(E)-4-(2-(pyridin-4-yl)vinyl)phenol;4-[2-(Pyridin-4-yl)ethenyl]phenol
• CAS NO: 67882-97-7
• Molecular Formula: C₁₃H₁₁NO
• Molecular Weight: 197.23254
• Mol File: 67882-97-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-4-(4-Hydroxystyryl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(4-Hydroxystyryl)pyridine(67882-97-7)
• EPA Substance Registry System: (E)-4-(4-Hydroxystyryl)pyridine(67882-97-7)

Safety Data

• Hazardous Substances Data: 67882-97-7(Hazardous Substances Data)

Usage

Description

(E)-4-(4-Hydroxystyryl)pyridine, also known as HSP, is a chemical compound with the molecular formula C14H11NO. It is a derivative of pyridine and has a distinct structure with a hydroxyl group and a styryl group attached to the pyridine ring. This unique structure endows it with various properties that make it a versatile compound for different applications.

Uses

Used in Research Applications:
(E)-4-(4-Hydroxystyryl)pyridine is used as a fluorescent probe for studying lipid bilayers. Its fluorescent properties allow researchers to gain insights into the structure and dynamics of these biologically important membranes.
Used in pH-Sensitive Dye Applications:
(E)-4-(4-Hydroxystyryl)pyridine is used as a pH-sensitive dye, making it a valuable tool for monitoring pH changes in various environments, including biological systems and chemical reactions.
Used in Pharmaceutical Applications:
(E)-4-(4-Hydroxystyryl)pyridine is studied for its potential anti-cancer properties. It has shown the ability to inhibit cell growth and induce apoptosis in cancer cells, making it a promising candidate for the development of new cancer therapies.
Used in Drug Delivery Systems:
(E)-4-(4-Hydroxystyryl)pyridine has also shown promise in applications for drug delivery systems. Its unique structure and properties can be harnessed to improve the delivery and efficacy of various therapeutic agents.
Used in Organic Light-Emitting Diode (OLED) Applications:
(E)-4-(4-Hydroxystyryl)pyridine is used as a material for organic light-emitting diodes. Its electronic and optical properties make it suitable for use in the development of advanced display technologies and lighting solutions.

Upstream product

• 108-89-4 picoline 
• 123-08-0 4-hydroxy-benzaldehyde 
• 2298-21-7 trans-4-acetoxy-4'-stilbazole 
• 722-21-4 (E)-4-(4-methoxystyryl)pyridine 
• 1145-93-3 diethyl 4-methoxybenzylphosphonate 
• 121-98-2 methyl 4-methoxybenzoate 
• 824-94-2 p-methoxybenzyl chloride 
• 105-13-5 4-Methoxybenzyl alcohol 
• 99-96-7 4-hydroxy-benzoic acid 
• 28356-58-3 pyridine-4-acetic acid 
• 100-43-6 4-vinylpyridine 
• 106-41-2 4-bromo-phenol 
• 55-22-1 pyridine-4-carboxylic acid 

Downstream Products

• 263872-14-6 1-(4-hydroxyphenyl)-2-(4-pyridyl)ethane 
• 118160-67-1 1-(4-Bromo-butyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-74-0 1-(4-Bromomethyl-benzyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 116223-44-0 trans-4-ethoxy-4'-stilbazole 
• 118160-68-2 1-(5-Bromo-pentyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-69-3 1-(6-Bromo-hexyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-71-7 1-(8-Bromo-octyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-70-6 1-(7-Bromo-heptyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-72-8 1-(9-Bromo-nonyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 122408-78-0 trans-4-<(4-methoxybenzoyl)oxy>-4'-stilbazole 
• 118160-73-9 1-(10-Bromo-decyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 118160-65-9 1-(2-Bromo-ethyl)-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-pyridinium; bromide 
• 139748-84-8 (E)-N-p-Bromobenzyl-γ-azastilbenol-4' bromide 

Relevant articles and documents

Hydrogen bonding and the design of twist-bend nematogens

The phase properties of equimolar mixtures consisting of a hydrogen bond donor, a 4-alkoxybenzoic acid (nOBA), and one of two different stilbazole-based hydrogen bond acceptors, either 4-[(E)-2-(4-{[6-(4′-methoxy[1,1′-biphenyl]-4-yl)hexyl]oxy}phenyl)-ethenyl]-pyridine (1OB6OS) or 4-[(E)-4′-(6-{4-[(E)-2-(pyridin-4-yl)ethenyl]phenoxy}hexyl)-[1,1′-biphenyl]-4-carbonitrile (CB6OS) are reported. Neither hydrogen bond acceptor exhibits liquid crystal behaviour whereas the nOBA compounds show smectic and/or nematic behaviour depending on the length of the alkyloxy chain. For the complexes of an nOBA with n = 1–5, both conventional nematic and twist-bend nematic phases were observed, while for n ≥ 6 smectic phases emerged and the twist-bend nematic phase was extinguished. The CB6OS-nOBA mixtures may exhibit the heliconical smectic CTB phase. The local molecular arrangement in the two sets of mixtures are similar and changes on increasing n but this is not reflected in the nematic-isotropic transition temperatures. Birefringence studies of the mixtures are reported. In general the behaviour of the hydrogen-bonded mixtures is similar to that of their covalently bonded counterparts.

Spontaneous chirality through mixing achiral components: A twist-bend nematic phase driven by hydrogen-bonding between unlike components

The spontaneous formation of a chiral phase via molecular recognition in a system consisting of achiral components is reported. Specifically, the liquid crystalline behaviour of two molecular complexes assembled by hydrogen bonding between a stilbazole-ba

Inhibitory effect of cytotoxic nitrogen-containing heterocyclic stilbene analogues on VEGF protein secretion and VEGF, hTERT and c-Myc gene expression

A group of 21 nitrogen-containing heterocyclic stilbene derivatives, prepared by means of Heck coupling reactions, has been investigated for their cytotoxicity as well as their ability to inhibit the production of the vascular endothelial growth factor (VEGF) and the activation of telomerase. The ability of these compounds to inhibit proliferation of two tumoral cell lines (HT-29 and MCF-7) and one non-tumoral cell line (HEK-293) was first determined. Subsequently, we determined the capacity of the compounds to inhibit the secretion of VEGF in the aforementioned cell lines and downregulate the expression of the VEGF, hTERT and c-Myc genes, of which the latter two are involved in controlling the activation of telomerase.